<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03663725</url>
  </required_header>
  <id_info>
    <org_study_id>StrateGlio-1802</org_study_id>
    <secondary_id>2018-000410-38</secondary_id>
    <nct_id>NCT03663725</nct_id>
  </id_info>
  <brief_title>Treatment Intensification With Temozolomide in Adults With a Glioblastoma</brief_title>
  <acronym>StrateGlio</acronym>
  <official_title>Phase III Randomised Trial Evaluating Treatment Intensification With Temozolomide in Adults With a Glioblastoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Oscar Lambret</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Association de Neuro-Oncologues d’Expression Francaise</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Erasme University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Centre Oscar Lambret</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Due to conflicting data on the optimal moment to start TMZ chemotherapy and the impact of
      prolongation of the adjuvant phase with TMZ, the ANOCEF (Association des Neuro-Oncologues
      d'Expression Francophone) group proposes this randomized trial comparing an intensified arm
      (early TMZ and extended adjuvant TMZ until toxicity, progression or patient refusal) versus
      the classical EORTC regimen as control (RT and concomitant TMZ started 4-6 weeks after
      surgery followed by a number of adjuvant TMZ cycles strictly limited to 6) for primary GBM
      adult patients.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 13, 2019</start_date>
  <completion_date type="Anticipated">May 1, 2023</completion_date>
  <primary_completion_date type="Anticipated">May 1, 2022</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>up to 18 months after recruitment of the last patient</time_frame>
    <description>time interval from randomization to death whatever the cause</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of adverse events</measure>
    <time_frame>up to 18 months after recruitment of the last patient</time_frame>
    <description>from randomization until disease progression - reported and graded using the NCI-CTCAE v5.0 classification</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival</measure>
    <time_frame>up to 18 months after recruitment of the last patient</time_frame>
    <description>time interval from randomization to the first occurrence of progression according to RANO criteria as assessed by the treating physician, or death whatever the cause</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">535</enrollment>
  <condition>Glioblastoma</condition>
  <arm_group>
    <arm_group_label>Intensified protocol</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Early Temozolomide (TMZ) Concomitant TMZ Adjuvant TMZ Prolonged TMZ</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Stupp protocol</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Concomitant Temozolomide (TMZ) Adjuvant TMZ</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Intensified protocol</intervention_name>
    <description>Early Temozolomide (TMZ) 1 cycle (150 mg/m²/ day X 5 days, per os) Started between day 2 and 15 after surgery/ biopsy RT (60 Gy, 2 Gy/fraction) + concomitant TMZ (75 mg/m2/day X 42 days, per os) Started between W4 and W6 after surgery/ biopsy Adjuvant TMZ 6 cycles (150-200 mg/m2 X 5 days /month, per os) Started 1 month after the end of the concomitant TMZ Prolonged TMZ Until progression, intolerance, patient's or physician's decision (150-200 mg/m2 every 4 weeks, per os)</description>
    <arm_group_label>Intensified protocol</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Stupp protocol</intervention_name>
    <description>RT (60 Gy, 2 Gy/fraction) + concomitant Temozolomide (75 mg/m2/day X 42 days, per os) Started between W4 and W6 after surgery/ biopsy Adjuvant TMZ 6 cycles (150-200 mg/m2 X 5 days /month, per os) Started 1 month after the end of the concomitant TMZ</description>
    <arm_group_label>Stupp protocol</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient ≥18 years old

          -  Histological diagnosis of de novo GBM (extemporaneous diagnosis or standard
             pathological examination). In case of extemporaneous diagnosis, the patient can be
             included. If the diagnosis is not confirmed, the patient will be withdrawn from study.

          -  Time between initial surgery/biopsy and planned start of treatment (if allocated to
             the experimental arm) ≤ 15 days (ideally in the first 7 days)

          -  Karnofsky performance status (KPS) ≥ 60%, or KPS &lt;60% only related to glioma-related
             motor paresis.

          -  Adequate biological functions

          -  Common toxicity criteria (CTC) non hematological adverse events ≤ Grade 1 (except for
             alopecia, nausea, vomiting and neurological symptoms)

          -  Females of child bearing potential must have a negative serum or urine pregnancy test
             within 7 days prior to initiation of treatment. Sexually active patients must agree to
             use adequate and appropriate contraception while on study drug and for 6 months after
             stopping the study drug.

          -  Standard radiation therapy deemed feasible (60 Gy, 30 fractions)

          -  Time interval of less than 43 days between initial surgery/biopsy and planned start of
             radiation therapy

          -  Written informed consent

        Exclusion Criteria:

          -  Secondary or recurrent glioblastoma (GBM)

          -  Planned use of tumor-treating electric fields

          -  Planned use of Carmustine implants

          -  Prior malignancy in the last 5 years before inclusion or concomitant

          -  Severe myelosuppression

          -  Known hypersensitivity to any of the study drugs, study drug classes, excipients in
             the formulation or to dacarbazine (DTIC)

          -  Current or recent treatment with another experimental drug or patients included in a
             clinical therapeutic trial (in the 30 days prior to inclusion).

          -  Known current viral hepatitis, HIV infection or current active infectious disease

          -  Inability to swallow oral medications or any mal-absorption condition

          -  Pregnant or breastfeeding patients.

          -  Inability to comply with medical follow-up of the trial (geographical, social or
             psychic reasons)

          -  Person under guardianship or curatorship
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Florence LEFRANC, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>ERASME</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Bruno CHAUFFERT, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHU Amiens</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Marie VANSEYMORTIER</last_name>
    <phone>33320295918</phone>
    <email>promotion@o-lambret.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Centre Hospitalier d'Amiens</name>
      <address>
        <city>Amiens</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>CHAUFFERT Bruno, MD PhD</last_name>
      <email>Chauffert.Bruno@chu-amiens.fr</email>
    </contact>
    <investigator>
      <last_name>Bruno CHAUFFERT, MD PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>May 2019</verification_date>
  <study_first_submitted>September 4, 2018</study_first_submitted>
  <study_first_submitted_qc>September 6, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">September 10, 2018</study_first_posted>
  <last_update_submitted>May 13, 2019</last_update_submitted>
  <last_update_submitted_qc>May 13, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">May 15, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>temozolomide</keyword>
  <keyword>Stupp protocol</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glioblastoma</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

